Investors

Company Profile

VistaGen Therapeutics (Nasdaq: VTGN) is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen's CNS drug candidates, PH94B, PH10, and AV-101, has a differentiated mechanism of action, a favorable safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets.

Data as of Aug 9, 2022 | 7:02 AM EDT

SEC Filings

Latest Quarterly or Annual Filing

Annual report which provides a comprehensive overview of the company for the past year

View Filing View All SEC Filings